Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer

Journal of Translational Medicine

Elise C Kohn¹  Minshu Yu¹  Min-Jung Lee²  Jane B Trepel²  Nicolas Gordon¹  Jung-Min Lee¹ 

[1] Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, 10 Center Dr. MSC1906, Building 10, Room 12N/226, Bethesda 20892-1906, MD, USA;Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda 20892, MD, USA

关键词: RAD51;    MRE11;    γH2AX;    Peripheral blood mononuclear cells;    Flow cytometry;    Biomarkers;    PARP inhibitor;    Ovarian cancer;   

Others  :  1221440
DOI  :  10.1186/s12967-015-0604-z

 received in 2015-04-14, accepted in 2015-07-13,  发布年份 2015

【 摘 要 】

Objectives

PARP inhibitors (PARPi) are a novel class of drugs with activity in patients with acquired or germline homologous recombination (HR) deficiency-associated high-grade serous ovarian cancer (HGSOC). We hypothesized that measuring γH2AX as an indicator of DNA double-strand breaks (DSB), and MRE11 or RAD51 as an indicator of DSB repair, would reflect HR status and predict response to PARPi-based therapy. Our aim was to develop and use high-throughput multiparametric flow cytometry to quantify γH2AX with MRE11 or RAD51 in PBMCs as a readily available surrogate.

Methods

Healthy donor PBMCs were used for assay development and optimization. We validated induction of γH2AX, MRE11 and RAD51 by staining with fluorophore-conjugated antibodies. The multiparameter flow cytometric method was applied to PBMC samples from recurrent HGSOC patients who were treated with PARPi, olaparib and carboplatin.

Results

Stimulation was necessary for quantification of a DNA damage response to olaparib/carboplatin in healthy donor PBMCs. The flow cytometric protocol could not distinguish between cytoplasmic and nuclear RAD51, erroneously indicating activation in response to injury. Thus, MRE11 was selected as the marker of DSB repair. PBMCs from 15 recurrent HGSOC patients were then examined. Patients who did not respond to PARPi therapy had a significantly higher pre-treatment level of γH2AX (p = 0.01), and a higher ratio of γH2AX/MRE11 (11.0 [3.5–13.2] v. 3.3 [2.8–9.9], p < 0.03) compared with responders.

Conclusions

We successfully developed and applied a multiparameter flow cytometry assay to measure γH2AX and MRE11 in PBMCs. Prospective studies will be required to validate this surrogate biomarker assay as a potential predictive biomarker of PARPi-based therapy.

【 授权许可】

   
2015 Lee et al.

【 图 表 】

Figure1.

Figure2.

Figure3.

Figure4.

【 参考文献 】

• [1]Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014; 25:32-40.
• [2]O’Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol. 2014; 4:42.
• [3]Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al.. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014; 15:852-861.
• [4]Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S et al.. GammaH2AX and cancer. Nat Rev Cancer. 2008; 8:957-967.
• [5]Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA et al.. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem. 2003; 278:20303-20312.
• [6]Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 2000; 10:886-895.
• [7]Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene. 2007; 26:7749-7758.
• [8]Lee SA, Roques C, Magwood AC, Masson JY, Baker MD. Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression. DNA Repair (Amst). 2009; 8:170-181.
• [9]Valdiglesias V, Giunta S, Fenech M, Neri M, Bonassi S. gammaH2AX as a marker of DNA double strand breaks and genomic instability in human population studies. Mutat Res. 2013; 753:24-40.
• [10]Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ et al.. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res. 2010; 16:4532-4542.
• [11]Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M et al.. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011; 71:5626-5634.
• [12]Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S et al.. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010; 16:2344-2351.
• [13]Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhoi BP et al.. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int. 2012; 110:E1228-E1236.
• [14]Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF et al.. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 2010; 70:7017-7026.
• [15]Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE et al.. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One. 2011; 6:e26152.
• [16]Ghardi M, Moreels M, Chatelain B, Chatelain C, Baatout S. Radiation-induced double strand breaks and subsequent apoptotic DNA fragmentation in human peripheral blood mononuclear cells. Int J Mol Med. 2012; 29:769-780.
• [17]Muller WU, Bauch T, Stuben G, Sack H, Streffer C. Radiation sensitivity of lymphocytes from healthy individuals and cancer patients as measured by the comet assay. Radiat Environ Biophys. 2001; 40:83-89.
• [18]Lou JL, Chen ZJ, Wei J, He JL, Jin LF, Chen SJ et al.. Response of lymphocytes to radiation in untreated breast cancer patients as detected with three different genetic assays. Biomed Environ Sci. 2008; 21:499-508.
• [19]Kryscio A, Ulrich Muller WU, Wojcik A, Kotschy N, Grobelny S, Streffer C. A cytogenetic analysis of the long-term effect of uranium mining on peripheral lymphocytes using the micronucleus-centromere assay. Int J Radiat Biol. 2001; 77:1087-1093.
• [20]Chung EJ, Lee S, Sausville EA, Ryan Q, Karp JE, Gojo I et al.. Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. Ann Clin Lab Sci. 2005; 35:397-406.
• [21]Virador VM, Davidson B, Czechowicz J, Mai A, Kassis J, Kohn EC. The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome. PLoS One. 2009; 4:e5136.
• [22]Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA et al (2014) Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 106:dju089
• [23]Collins RJ, Harmon BV, Souvlis T, Pope JH, Kerr JF. Effects of cycloheximide on B-chronic lymphocytic leukaemic and normal lymphocytes in vitro: induction of apoptosis. Br J Cancer. 1991; 64:518-522.
• [24]Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
• [25]Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009; 461:1071-1078.
• [26]Carreira A, Kowalczykowski SC. Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanisms. Proc Natl Acad Sci USA. 2011; 108:10448-10453.
• [27]Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC et al (2010) PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2:53ra75
• [28]Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J et al.. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010; 16:6159-6168.
• [29]Kim TM, Son MY, Dodds S, Hu L, Hasty P. Deletion of BRCA2 exon 27 causes defects in response to both stalled and collapsed replication forks. Mutat Res Fundam Mol Mech Mutagen. 2014; 766–767:66-72.
• [30]Symington LS. DNA repair: making the cut. Nature. 2014; 514:39-40.
• [31]Cannavo E, Cejka P. Sae2 promotes dsDNA endonuclease activity within Mre11-Rad50-Xrs2 to resect DNA breaks. Nature. 2014; 514:122-125.
• [32]Mirzoeva OK, Petrini JH. DNA replication-dependent nuclear dynamics of the Mre11 complex. Mol Cancer Res. 2003; 1:207-218.
• [33]Hartlerode A, Odate S, Shim I, Brown J, Scully R. Cell cycle-dependent induction of homologous recombination by a tightly regulated I-SceI fusion protein. PLoS One. 2011; 6:e16501.
• [34]Martin M, Terradas M, Hernandez L, Genesca A. gammaH2AX foci on apparently intact mitotic chromosomes: not signatures of misrejoining events but signals of unresolved DNA damage. Cell Cycle. 2014; 13:3026-3036.
• [35]Mirzoeva OK, Petrini JH. DNA damage-dependent nuclear dynamics of the Mre11 complex. Mol Cell Biol. 2001; 21:281-288.
• [36]Kim JS, Krasieva TB, Kurumizaka H, Chen DJ, Taylor AM, Yokomori K. Independent and sequential recruitment of NHEJ and HR factors to DNA damage sites in mammalian cells. J Cell Biol. 2005; 170:341-347.
• [37]Zhao H, Traganos F, Albino AP, Darzynkiewicz Z. Oxidative stress induces cell cycle-dependent Mre11 recruitment, ATM and Chk2 activation and histone H2AX phosphorylation. Cell Cycle. 2008; 7:1490-1495.
• [38]Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V et al.. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011; 71:2632-2642.
• [39]Koppensteiner R, Samartzis EP, Noske A, von Teichman A, Dedes I, Gwerder M et al.. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS One. 2014; 9:e100041.
• [40]Albino AP, Huang X, Jorgensen E, Yang J, Gietl D, Traganos F et al.. Induction of H2AX phosphorylation in pulmonary cells by tobacco smoke: a new assay for carcinogens. Cell Cycle. 2004; 3:1062-1068.
• [41]Wang Z, Hu H, Hu M, Zhang X, Wang Q, Qiao Y et al.. Ratio of gamma-H2AX level in lymphocytes to that in granulocytes detected using flow cytometry as a potential biodosimeter for radiation exposure. Radiat Environ Biophys. 2014; 53:283-290.
• [42]Porcedda P, Turinetto V, Brusco A, Cavalieri S, Lantelme E, Orlando L et al.. A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry A. 2008; 73:508-516.
• [43]Kataoka Y, Bindokas VP, Duggan RC, Murley JS, Grdina DJ. Flow cytometric analysis of phosphorylated histone H2AX following exposure to ionizing radiation in human microvascular endothelial cells. J Radiat Res. 2006; 47:245-257.
• [44]Beaton LA, Marro L, Malone S, Samiee S, Grimes S, Malone K et al.. Investigating gamma H2AX as a biomarker of radiosensitivity using flow cytometry methods. ISRN Radiol. 2013; 2013:704659.
• [45]Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC et al.. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013; 129:86-91.
• [46]Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J et al.. A novel platform for detection of CK+ and CK− CTCs. Cancer Discov. 2011; 1:580-586.
• [47]Hoeller U, Borgmann K, Bonacker M, Kuhlmey A, Bajrovic A, Jung H et al.. Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol. 2003; 69:137-144.
• [48]Riches AC, Bryant PE, Steel CM, Gleig A, Robertson AJ, Preece PE et al.. Chromosomal radiosensitivity in G2-phase lymphocytes identifies breast cancer patients with distinctive tumour characteristics. Br J Cancer. 2001; 85:1157-1161.
• [49]Lisowska H, Lankoff A, Wieczorek A, Florek A, Kuszewski T, Gozdz S et al.. Enhanced chromosomal radiosensitivity in peripheral blood lymphocytes of larynx cancer patients. Int J Radiat Oncol Biol Phys. 2006; 66:1245-1252.